Inhibition of FABP4 reduced metastatic tumor burden in vivo [80,81], and also increased the sensitivity of OvCa cells toward carboplatin when treated with a small-molecule inhibitor of FABP4 (BMS309403) [80]. Here, FABP4 is linked to neoplasm.